about
HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance PSelective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndromeA sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in traNeurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNSNeurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.Measurement of plasma-derived substance P: biological, methodological, and statistical considerations.Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation.Human immunodeficiency virus and depression in primary care: a clinical review.Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS.An in vitro model of morphine withdrawal manifests the enhancing effect on human immunodeficiency virus infection of human T lymphocytes through the induction of substance P.Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor.Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis.Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions.Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIVSubstance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R)Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells.The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain.Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.Involvement of substance P and the NK-1 receptor in pancreatic cancer.Tachykinins and Neurokinin Receptors in Bone Marrow Functions: Neural-Hematopoietic Link.Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis.Substance P-mediated chemokine production promotes monocyte migration.Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.Novel method for determination of substance P levels in unextracted human plasma by using acidification.Substance P protects against hyperoxic-induced lung injury in neonatal rats.Blood-brain barrier abnormalities caused by HIV-1 gp120: mechanistic and therapeutic implications.
P2860
Q33750864-84E75677-DD98-40BB-9192-59DEB58DA6B7Q33752757-EC17568B-9884-4108-A85F-145DE8C19DC1Q33906832-EB7BAFBE-FF91-4EC0-94D6-441489438A29Q34086928-E6063549-C70C-4033-92FC-1CC2CDB17828Q34150798-092D082D-3490-42BE-9E91-4D83557F056FQ34565970-84F87D75-719A-40E6-B20B-130554D65F1EQ34591209-3AE73236-A016-4067-BB24-B79663F6117EQ35011997-4335E2B8-8B56-49C9-AF0A-5DAA6F42C2A2Q35177355-4CEF3FA8-C581-4D31-87CA-FF09C87A9B17Q35607410-61C988C5-49EC-4CBF-91F7-5E5872E5A20CQ35755634-7F4423D6-C132-471B-A28E-8D9C778DFC66Q35973463-1F70C451-0D05-467C-84A6-EB876756F698Q36164951-02F2ADAD-3DAA-48E1-9F0B-609A863E4BA0Q36460037-0CCA12A6-E365-4D9D-AB51-3CD5A7D4F2B9Q36937565-469FD882-52AC-4683-B868-92EEB34433F5Q37034775-2050AE1A-37CA-418F-9E89-A452900CAB9BQ37062163-3F1580F1-019B-4A18-AD9B-86C3AEDEFDF9Q37074777-0DAE5012-CD83-42EB-90F3-61CE23B5B4D5Q37149019-78FCBC2D-2772-4806-AC0F-202F5C3646EEQ37340453-4958E03A-633F-4959-810E-C37921A3892BQ37617971-9762A62B-FCDF-455D-932B-AB6F6BCCA838Q37769121-66025E0C-F53E-42FE-8CEF-85BCA762478FQ40085168-09126EF0-612F-45E4-85B4-235006CC17B3Q40268840-FE1D1F5F-B0B2-477A-916B-FFE308DA788BQ41924104-A263AFA7-B892-4F6C-98B0-41838D38D7A2Q43146586-C1EE7E5F-537C-42EA-A093-2445CD3D1A9AQ46831097-B87E5B7E-67A9-41D9-A8A4-FA1D92BF7892Q52623530-46AA0EE7-F184-4B8B-ACC9-37248D7DDEF2
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Substance P and neurokinin-1 receptor modulation of HIV
@ast
Substance P and neurokinin-1 receptor modulation of HIV
@en
Substance P and neurokinin-1 receptor modulation of HIV
@nl
type
label
Substance P and neurokinin-1 receptor modulation of HIV
@ast
Substance P and neurokinin-1 receptor modulation of HIV
@en
Substance P and neurokinin-1 receptor modulation of HIV
@nl
prefLabel
Substance P and neurokinin-1 receptor modulation of HIV
@ast
Substance P and neurokinin-1 receptor modulation of HIV
@en
Substance P and neurokinin-1 receptor modulation of HIV
@nl
P3181
P1476
Substance P and neurokinin-1 receptor modulation of HIV
@en
P2093
Steven D Douglas
Wen-Zhe Ho
P3181
P356
10.1016/J.JNEUROIM.2004.08.022
P407
P577
2004-12-01T00:00:00Z